| [1] |
Wang H, Jiang W, Zhou Z, et al. Liver transplantation in mainland China: the overview of CLTR 2011 annual scientific report[J]. Hepatobiliary Surg Nutr, 2013, 2(4):188-197. http://cn.bing.com/academic/profile?id=2148612613&encoded=0&v=paper_preview&mkt=zh-cn
|
| [2] |
Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience[J]. Liver Transpl, 2011, 17(Suppl 2):S44-S57. http://cn.bing.com/academic/profile?id=2008655007&encoded=0&v=paper_preview&mkt=zh-cn
|
| [3] |
Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria[J]. Am J Transplant, 2008, 8(10):1982-1989. doi: 10.1111/ajt.2008.8.issue-10
|
| [4] |
Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis[J]. Lancet Oncol, 2009, 10(1):35-43. doi: 10.1016/S1470-2045(08)70284-5
|
| [5] |
Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences[J]. Transplantation, 2008, 85(12):1726-1732. doi: 10.1097/TP.0b013e31816b67e4
|
| [6] |
Fan J, Yang GS, Fu ZR, et al. Liver transplantation outcomes in 1, 078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China[J]. J Cancer Res Clin Oncol, 2009, 135(10):1403-1412. doi: 10.1007/s00432-009-0584-6
|
| [7] |
Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria[J]. Gastroenterology, 2012, 143(4):986-994. doi: 10.1053/j.gastro.2012.05.052
|
| [8] |
Pompili M, Francica G, Ponziani FR, et al. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation[J]. World J Gastroenterol, 2013, 19(43):7515-7530. doi: 10.3748/wjg.v19.i43.7515
|
| [9] |
Ettorre GM, Laurenzi A, Vennarecci G. Downstaging Hepatocellular Carcinoma with Yttrium-90 radioembolization: resection or transplantation?[J]. Eur J Surg Oncol, 2014, DOI: 10.1016/j.ejso.2014.01.017[Epub ahead of print].
|
| [10] |
Barry CT, D'Souza M, McCall M, et al. Micro RNA expression profiles as adjunctive data to assess the risk of hepatocellular carcinoma recurrence after liver transplantation[J]. Am J Transplant, 2012, 12(2):428-437. doi: 10.1111/j.1600-6143.2011.03788.x
|
| [11] |
Bai DS, Dai Z, Zhou J, et al. Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma[J]. Hepatology, 2009, 49(2):460-470. doi: 10.1002/hep.22638
|
| [12] |
Wang GY, Yang Y, Li H, Zhang J, et al. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation[J]. PLoS One, 2011, 6(9):e25295. doi: 10.1371/journal.pone.0025295
|
| [13] |
Takada Y, Kaido T, Asonuma K, et al. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation[J]. Liver Transpl, 2013, 19(8):896-906. doi: 10.1002/lt.23679
|
| [14] |
Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2013, 37(4):411-419. doi: 10.1111/apt.12185
|
| [15] |
Schnitzbauer AA, Zuelke C, Graeb C, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma[J]. BMC Cancer, 2010, 10:190. doi: 10.1186/1471-2407-10-190
|
| [16] |
Alegre C, Jiménez C, Manrique A, et al. Everolimus monotherapy or combined therapy in liver transplantation: indications and results[J]. Transplant Proc, 2013, 45(5):1971-1974. doi: 10.1016/j.transproceed.2013.01.075
|
点击查看大图
下载:
